A randomized, open-label, 2-period, crossover pharmacokinetic study to evaluate, after single and multiple doses, whether esomeprazole magnesium (Nexium) 40 mg opened capsule in water, administered through a nasogastric tube, is bioequivalent to an intact 40 mg capsule, administered orally, in healthy subjects

Study identifier:SH-QBE-0096

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomized, open-label, 2-period, crossover pharmacokinetic study to evaluate, after single and multiple doses, whether esomeprazole magnesium (Nexium) 40 mg opened capsule in water, administered through a nasogastric tube, is bioequivalent to an intact 40 mg capsule, administered orally, in healthy subjects

Medical condition

gastrointestinal diseases

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria